The DEA's plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
Dr. Roger McIntyre suggests that the clinical relevance of cognitive dysfunction for any individual patient can only be adjudicated on a case-by-case basis.
The researchers observed between-group differences between real and sham acupuncture treatment.
Studies have found only small improvements in treating depression with Omega-3s and have been of low-quality.
Patients with psychosis and addiction disorders responded moderately better to disorder-specific treatment.
Patients in coordinated care remained in treatment longer and experienced greater improvements in their symptoms, compared with standard-care patients.
Psychiatry Advisor Articles
- The Current State of Autism: From Etiology to Treatment
- Augmentation Therapy for Treatment-Resistant Major Depressive Disorder
- Long-Term Cariprazine Safe, Tolerable for Schizophrenia
- Why Do Antipsychotics Cause Weight Gain?
- Is Aspirin Use Associated With a Decreased Incidence of Depressive Symptoms?
- emPATH Units as a Solution for ED Psychiatric Patient Boarding
- Antidepressants for Poststroke Depression: Comparative Efficacy and Acceptability
- New Model Shows High Accuracy in Predicting Response to Lithium
- Frequent Cannabis Use Associated With Increased Likelihood of MDD
- Protecting the Brain: The Damaging Impact of Traumatic Brain Injury
- Juvenile Bipolar Disorder: Intranasal Ketamine Effective, Well-Tolerated
- When Patients Are Pathological Liars: Implications For for Psychiatrists
- PTSD and Fibromyalgia: Can Opioid Combination Therapy Improve QOL?
- Psychotic Experiences Associated With Subsequent Suicidal Thoughts
- Cognitive Impairment in Adults With Depression Identified by THINC-it Screening Tool